ARTERIAL HYPERTENSION AND ERECTILE DYSFUNCTION: COMMON PATHOGENETIC MECHANISMS AND THERAPEUTIC POTENTIAL OF IRBESARTAN
Keywords:
arterial hypertension, erectile dysfunction, endothelial dysfunction, renin–angiotensin–aldosterone system .Abstract
Arterial hypertension (AH) and erectile dysfunction (ED) are interrelated clinical conditions whose pathogenesis involves endothelial dysfunction, reduced nitric oxide bioavailability, overactivation of the renin–angiotensin–aldosterone system (RAAS), oxidative stress, and impaired vascular regulation. The commonality of these mechanisms supports interest in the potential role of antihypertensive therapy, particularly angiotensin II receptor blockers (ARBs), including irbesartan, in patients with concomitant AH and ED.
References
1.McEvoy JW, McCarthy CP, Bruno RM et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45(38):3912–4018.
2.Burnett AL, Nehra A, Breau RH et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633–641.
3.Solomon H., Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003;89(3):251–253.
4.Vanhoutte PM, Shimokawa H., Feletou M., Tang EHC Endothelial dysfunction and vascular disease—a 30th anniversary update. Acta Physiol . 2017;219(1):22–96.
5.Montorsi P., Ravagnani PM, Galli S. et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol . 2005;96(12B):19M–23M.
6.Vlachopoulos C., Jackson G., Stefanadis C., Montorsi P. Erectile dysfunction in the cardiovascular patient. Eur Heart J 2013;34(27):2034–2046.
7.Miner M., Seftel AD, Nehra A., Ganz P. Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart J 2012;164(2):149–155.
8.European Association of Urology. EAU Guidelines on Sexual and Reproductive Health. Arnhem : EAU Guidelines Office; 2024.
9.Andersson KE Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev . 2011;63(4):811–859.
10.Dean RC, Lue TF Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am . 2005;32(4):379–395.
11.Dzau VJ Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension . 2001;37(4):1047–1052.
12.Wolf G. Free radical production and angiotensin. Curr Hypertens Rep . 2000;2(2):167–173.
13.SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med . 2015;373(22):2103–2116.
14.Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med . 2001;345(12):851–860.
15.Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med . 2001;345(12):870–878.
16.Kassler-Taub K., Littlejohn T., Elliott W., Ruddy T., Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens . 1998;11(4 Pt 1):445–453.